Sana Biotechnology Inc (SANA)
8.43
-0.12
(-1.40%)
USD |
NASDAQ |
May 17, 12:08
Sana Biotechnology Cash from Operations (Quarterly): -65.63M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -65.63M |
| December 31, 2023 | -51.96M |
| September 30, 2023 | -63.55M |
| June 30, 2023 | -58.80M |
| March 31, 2023 | -79.27M |
| December 31, 2022 | -76.07M |
| September 30, 2022 | -64.80M |
| June 30, 2022 | -71.48M |
| March 31, 2022 | -77.71M |
| Date | Value |
|---|---|
| December 31, 2021 | -110.10M |
| September 30, 2021 | -50.49M |
| June 30, 2021 | -40.56M |
| March 31, 2021 | -49.91M |
| December 31, 2020 | -37.56M |
| September 30, 2020 | -37.51M |
| June 30, 2020 | -33.37M |
| March 31, 2020 | -29.55M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-110.10M
Minimum
Dec 2021
-29.55M
Maximum
Mar 2020
-58.72M
Average
-58.80M
Median
Jun 2023
Cash from Operations (Quarterly) Benchmarks
| Rocket Pharmaceuticals Inc | -56.86M |
| Solid Biosciences Inc | -20.82M |
| Dyne Therapeutics Inc | -78.54M |
| Taysha Gene Therapies Inc | -19.80M |
| Tenaya Therapeutics Inc | -28.66M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -77.23M |
| Cash from Financing (Quarterly) | 186.40M |
| Free Cash Flow | -273.64M |
| Free Cash Flow Per Share (Quarterly) | -0.375 |
| Free Cash Flow Yield | -16.08% |